Cancer statistics for African Americans, 2013

CA Cancer Journal for Clinicians

Volumn 63, Issue 3, 2013, Pages 151-166

  Desantis, Carol ^a   Naishadham, Deepa ^a   Jemal, Ahmedin ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

African American; cancer; health disparities; mortality; survival

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; BREAST CANCER; BRONCHUS CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER REGISTRY; CANCER STAGING; CANCER STATISTICS; CANCER SURVIVAL; CAUCASIAN; COLORECTAL CANCER; CONTROLLED STUDY; EARLY DIAGNOSIS; ETHNIC DIFFERENCE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH SERVICE; SEX DIFFERENCE; SURVIVAL RATE; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; EARLY DETECTION OF CANCER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 84877257060     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21173     Document Type: Article

References (95)

1. Surveillance, Epidemiology, and End Results (SEER) Program. SEERStat Database: Incidence-SEER 9 Regs Research Data, Nov. 2011 Sub, Vintage 2009 Pops (1973-2009) -Linked To County Attributes-Total US, 1969-2010 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2012, based on the November 2011 submission.
2. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2012.
3. Surveillance, Epidemiology, and End Results (SEER) Program. SEERStat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov. 2011 Sub (1973-2009 varying)-Linked To County Attributes-Total US, 1969-2010 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2012, based on the November 2011 submission.
4. Surveillance, Epidemiology and End Results (SEER) Program. SEERStat Database: North American Association of Central Cancer Registries (NAACCR) Incidence-CiNA Analytic File, 1995-2009. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2012.
5. Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
6. Surveillance, Epidemiology, and End Results (SEER) Program. SEERStat Database: Mortality-All COD, Aggregated With State, Total US (1969-2009) . Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2012. Released April 2012; underlying mortality data provided by National Center for Health Statistics.
7. Surveillance Research Program. National Cancer Institute SEERStat software. Version 7.1.0. Bethesda, MD: National Cancer Institute; 2012.
8. Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels [published online ahead of print January 7, 2013 ]. J Natl Cancer Inst. doi: 10.1093/jnci/djs491.
9. Zhu L, Pickle LW, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence. Cancer. 2012; 118: 1100-1109.
10. Pickle LW, Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin. 2007; 57: 30-42.
11. Chen HS, Portier K, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: Part I: evaluation of temporal projection methods for mortality. Cancer. 2012; 118: 1091-1099.
12. DevCan: Probability of Developing or Dying of Cancer Software. Version 6.6.1. Bethesda, MD: Statistical Research and Applications Branch, National Cancer Institute; 2012.
13. National Center for Health Statistics. Data File Documentation, National Health Interview Survey, 2010 (machine Readable Data File and Documentation). Hyattsville, MD: National Center for Health Statistics; 2011.
14. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ,. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 2002; 94: 1204-1210.
15. Epplein M, Signorello LB, Zheng W, et al. Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev. 2011; 20: 826-834.
16. Kelley JR, Duggan JM,. Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003; 56: 1-9.
17. Greenberg AJ, Vachon CM, Rajkumar SV,. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia. 2012; 26: 609-614.
18. Jemal A, Center MM, Ward E,. The convergence of lung cancer rates between blacks and whites under the age of 40, United States. Cancer Epidemiol Biomarkers Prev. 2009; 18: 3349-3352.
19. Simard EP, Naishadham D, Saslow D, Jemal A,. Age-specific trends in black-white disparities in cervical cancer incidence in the United States: 1975-2009. Gynecol Oncol. 2012; 127: 611-615.
20. DeLancey JO, Thun MJ, Jemal A, Ward E,. Recent trends in Black-White disparities in cancer mortality. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2908-2912.
21. Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008; 58: 9-31.
22. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB,. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002; 287: 2106-2113.
23. Shavers VL, Brown ML,. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002; 94: 334-357.
24. Smedley BD, Stith AY, Nelson AR, eds; Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academies Press; 2002.
25. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004; 101: 3-27.
26. Komenaka IK, Martinez ME, Pennington RE Jr, et al. Race and ethnicity and breast cancer outcomes in an underinsured population. J Natl Cancer Inst. 2010; 102: 1178-1187.
27. Du XL, Lin CC, Johnson NJ, Altekruse S,. Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival: findings from the National Longitudinal Mortality Study, 1979-2003. Cancer. 2011; 117: 3242-3251.
28. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL,. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009; 101: 984-992.
29. Alexander DD, Waterbor J, Hughes T, Funkhouser E, Grizzle W, Manne U,. African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review. Cancer Biomark. 2007; 3: 301-313.
30. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA,. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2006; 24: 1342-1349.
31. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D,. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005; 294: 1765-1772.
32. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998; 82: 2123-2134.
33. Wallace TA, Martin DN, Ambs S,. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis. 2011; 32: 1107-1121.
34. Murthy VH, Krumholz HM, Gross CP,. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291: 2720-2726.
35. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356: 1670-1674.
36. DeSantis C, Howlader N, Cronin KA, Jemal A,. Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev. 2011; 20: 733-739.
37. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502.
38. Li CI, Malone KE, Daling JR,. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002; 11: 601-607.
39. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005; 97: 439-448.
40. Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA,. Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat. 2010; 121: 281-292.
41. Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011; 103: 470-477.
42. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008; 109: 123-139.
43. Ursin G, Bernstein L, Lord SJ, et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer. 2005; 93: 364-371.
44. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007; 16: 439-443.
45. van Ravesteyn NT, Schechter CB, Near AM, et al. Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol Biomarkers Prev. 2011; 20: 112-122.
46. Curtis E, Quale C, Haggstrom D, Smith-Bindman R,. Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer. 2008; 112: 171-180.
47. Menashe I, Anderson WF, Jatoi I, Rosenberg PS,. Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst. 2009; 101: 993-1000.
48. Smith-Bindman R, Miglioretti DL, Lurie N, et al. Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann Intern Med. 2006; 144: 541-553.
49. Press R, Carrasquillo O, Sciacca RR, Giardina EG,. Racial/ethnic disparities in time to follow-up after an abnormal mammogram. J Womens Health (Larchmt). 2008; 17: 923-930.
50. Smith GL, Shih YC, Xu Y, et al. Racial disparities in the use of radiotherapy after breast-conserving surgery: a national Medicare study. Cancer. 2010; 116: 734-741.
51. Lund MJ, Brawley OP, Ward KC, Young JL, Gabram SS, Eley JW,. Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat. 2008; 109: 545-557.
52. Bickell NA, Wang JJ, Oluwole S, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006; 24: 1357-1362.
53. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V,. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109: 1721-1728.
54. Thomson CS, Hole DJ, Twelves CJ, Brewster DH, Black RJ,; Scottish Cancer Therapy Network. Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect on differences in survival. J Epidemiol Community Health. 2001; 55: 308-315.
55. Gordon NH,. Socioeconomic factors and breast cancer in black and white Americans. Cancer Metastasis Rev. 2003; 22: 55-65.
56. Chen VW, Correa P, Kurman RJ, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev. 1994; 3: 127-135.
57. Jemal A, Center MM, DeSantis C, Ward EM,. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1893-1907.
58. Brawley OW, Berger MZ,. Cancer and disparities in health: perspectives on health statistics and research questions. Cancer. 2008; 113 (suppl 7): 1744-1754.
59. Brawley OW, Ankerst DP, Thompson IM,. Screening for prostate cancer. CA Cancer J Clin. 2009; 59: 264-273.
60. Etzioni R, Gulati R, Falcon S, Penson DF,. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making. 2008; 28: 323-331.
61. Chu KC, Tarone RE, Freeman HP,. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003; 97: 1507-1516.
62. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR,. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003; 95: 981-989.
63. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999; 91: 1017-1024.
64. Potosky AL, Feuer EJ, Levin DL,. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev. 2001; 23: 181-186.
65. Hsing AW, Devesa SS,. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev. 2001; 23: 3-13.
66. Andriole GL, Crawford ED, Grubb RL 3rd, et al. PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104: 125-132.
67. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010; 11: 725-732.
68. Schroder FH, Hugosson J, Roobol MJ, et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
69. Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA,. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010; 28: 1069-1074.
70. Kauh J, Brawley OW, Berger M,. Racial disparities in colorectal cancer. Curr Probl Cancer. 2007; 31: 123-133.
71. Doubeni CA, Major JM, Laiyemo AO, et al. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst. 2012; 104: 1353-1362.
72. Meissner HI, Breen N, Klabunde CN, Vernon SW,. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2006; 15: 389-394.
73. Centers for Disease Control and Prevention (CDC). Cancer screening-United States, 2010. MMWR Morb Mortal Wkly Rep. 2012; 61: 41-45.
74. Irby K, Anderson WF, Henson DE, Devesa SS,. Emerging and widening colorectal carcinoma disparities between Blacks and Whites in the United States (1975-2002). Cancer Epidemiol Biomarkers Prev. 2006; 15: 792-797.
75. Robbins AS, Siegel RL, Jemal A,. Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol. 2012; 30: 401-405.
76. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, van Ballegooijen M, Zauber AG, Jemal A,. Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev. 2012; 21: 728-736.
77. Polite BN, Dignam JJ, Olopade OI,. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol. 2006; 24: 2179-2187.
78. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF,. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002; 20: 1192-1202.
79. Dimou A, Syrigos KN, Saif MW,. Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol. 2009; 15: 3734-3743.
80. Jessup JM, Stewart A, Greene FL, Minsky BD,. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005; 294: 2703-2711.
81. Yothers G, Sargent DJ, Wolmark N, et al. ACCENT Collaborative Group. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011; 103: 1498-1506.
82. Benard VB, Howe W, Royalty J, Helsel W, Kammerer W, Richardson LC,. Timeliness of cervical cancer diagnosis and initiation of treatment in the National Breast and Cervical Cancer Early Detection Program. J Womens Health (Larchmt). 2012; 21: 776-782.
83. Horner MJ, Altekruse SF, Zou Z, Wideroff L, Katki HA, Stinchcomb DG,. U.S. geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality. Cancer Epidemiol Biomarkers Prev. 2011; 20: 591-599.
84. Cardin VA, Grimes RM, Jiang ZD, Pomeroy N, Harrell L, Cano P,. Low-income minority women at risk for cervical cancer: a process to improve adherence to follow-up recommendations. Public Health Rep. 2001; 116: 608-616.
85. Simard EP, Fedewa S, Ma J, Siegel R, Jemal A,. Widening socioeconomic disparities in cervical cancer mortality among women in 26 states, 1993-2007. Cancer. 2012; 118: 5110-5116.
86. Brookfield KF, Cheung MC, Lucci J, Fleming LE, Koniaris LG,. Disparities in survival among women with invasive cervical cancer: a problem of access to care. Cancer. 2009; 115: 166-178.
87. Coker AL, Du XL, Fang S, Eggleston KS,. Socioeconomic status and cervical cancer survival among older women: findings from the SEER-Medicare linked data cohorts. Gynecol Oncol. 2006; 102: 278-284.
88. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV,. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55: 244-265.
89. Insinga RP, Liaw KL, Johnson LG, Madeleine MM,. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1611-1622.
90. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years-United States, 2011. MMWR Morb Mortal Wkly Rep. 2012; 61: 671-677.
91. Anderson C, Burns DM,. Patterns of adolescent smoking initiation rates by ethnicity and sex. Tob Control. 2000; 9 (suppl 2): II4-II8.
92. National Center for Health Statistics. Health, United States, 2011: With Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics; 2012.
93. Cykert S, Dilworth-Anderson P, Monroe MH, et al. Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA. 2010; 303: 2368-2376.
94. Bach PB, Cramer LD, Warren JL, Begg CB,. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999; 341: 1198-1205.
95. Hardy D, Liu CC, Xia R, et al. Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer. Cancer. 2009; 115: 2199-2211.